ALG-125755 is under clinical development by Aligos Therapeutics and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALG-125755’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ALG-125755 overview

ALG-125755 is under development for the treatment of chronic hepatitis B. The drug candidate is a small interference RNA (siRNA) and acts by targeting hepatitis B virus surface antigen (HBsAg). It is administered through subcutaneous route. 

Aligos Therapeutics overview

Aligos Therapeutics, Inc (Aligos), is a clinical stage biopharmaceutical company that develops products for the treatment of viral infections and liver diseases. It develops pipeline products for the treatment of various viral infections that include chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), coronaviruses, and liver diseases. The company operates in the United States and Europe. Aligos is headquartered in South San Francisco, California, the United States.

For a complete picture of ALG-125755’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.